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Clonidine and Naltrexone: 
Rapid Treatment of Opioid Withdrawal in the Outpatient Setting 
Eugenia Marie Vining 
1987 
Clonidine hydrochloride (an alpha-2 adrenergic agonist) and 
naltrexone hydrochloride (an opioid antagonist), given in 
combination, provide a safe and effective treatment of abrupt 
opioid withdrawal over 4 or 5 days in an outpatient/day 
setting. Following a naloxone challenge test to verify and 
quantify opioid dependence, fourteen of 17 (82%) heroin users 
successfully withdrew from opioids and attained maintenance 
levels of naltrexone. Eight of 9 (89%) successfully completed 
the 5 day study in which naltrexone therapy was begun on day 
2. Six of 8 (75%) successfully completed the 4 day study in 
which naltrexone therapy was begun on day 1. Three to 5 days 
of clonidine hydrochloride treatment with a peak mean dose of 
0.6 mg/day on day 2 for the patients in the 5 day study, and 
0.5 mg on days 1 and 2 for patients in the 4 day study, 
attenuated the withdrawal inducing effects of naltrexone. Both 
groups received naltrexone in single morning doses which were 
rapidly increased from 12.5 mg on the first day of naltrexone 
therapy to 50 mg on the third day. Significant correlations 
were observed between naloxone challenge test score and 
IV 

observer-rated symptomatology during treatment. Clonidine 
significantly decreased blood pressure in both groups without 
producing clinical problems. This study has improved the 
availability of the clonidine-naltrexone combination by 
developing a single dose per day naltrexone regimen with 






The last of the codeine was running out. My nose and eyes 
began to run, sweat soaked through my clothes. Hot and cold 
flashes hit me as though a furnace door was swinging open and 
shut. My legs ached and twiched so that any position was 
intolerable, and I moved from one side to the other, sloshing 
about in my sweaty clothes. 
William S. Burroughs, Junkv 1953 
Opioid withdrawal, so vividly described by William S. Burroughs 
in his powerful account of heroin addiction, is a syndrome of 
autonomic disturbance and psychic distress which drives the addict 
to continued opioid use. This abstinence syndrome as well as 
tolerance to the effects of increasing amounts of opioids characterize 
opioid dependence (APA, 1980). Successful treatment of opioid 
dependence involves treatment of the withdrawal syndrome and 
assistance afterward so that the former addict can remain drug-free. 
At the turn of the century, treatment of narcotic addiction was 
often considered synonymous with successful withdrawal. New 
treatments were advanced periodically and then discarded as 
ineffective and often harmful. Sodium thiocyanate, lipids, sodium 
bromide, insulin and other hormones were just some of the agents 
used to "treat" opioid withdrawal (Kleber, 1982). One of the most 
popular methods of detoxification at this time employed belladonna 
agents (Kolb and Himmelsbach, 1938). Scopolomine was 
administered every 30 to 60 minutes over a one to two day period. 
During this detoxification patients would hallucinate and become 
wildly delirious, symptomatic of belladonna toxicity. Fortunately, 
such treatments were denounced as more distressing and harmful to 
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addicts than withdrawal itself; however, this was not until a number 
of deaths had already resulted from them. 
In their review article criticizing many of these forms of 
treatment, Kolb and Himmelsbach proposed a "rapid withdrawal" 
method of detoxification in which doses of morphine and codeine 
would be gradually tapered over a seven day period (Kolb and 
Himmelsbach, 1938). This method of detoxification would dominate 
treatment modalities until the discovery of methadone during the 
Second World War (Isbell et al, 1947). In addition, citing faulty 
observation of the course of withdrawal as the cause for failure of 
previous "treatments," these investigators outlined a quantitative 
method for measuring abstinence syndrome intensity. This method 
enabled objective evaluation of future treatment modalities and 
became the model for present day abstinence rating scales. 
Methadone was synthesized by the Germans during World War II, 
and soon underwent intensive clinical investigation in the United 
States (Isbell et al, 1947; Isbell et al, 1948). These studies revealed 
that methadone was an addictive substance that produced an 
abstinence syndrome with milder, more prolonged symptoms than 
morphine or heroin (Isbell et al, 1948). Investigators also found that 
methadone could prevent the abstinence syndrome in morphine 
dependent patients (Isbell et al, 1948). Researchers quickly realized 
the advantages of this cross tolerance. Placing morphine or heroin 
dependent patients on methadone would substitute the more intense 
abstinence syndrome produced by these short-acting opiates with 
the much milder withdrawal from methadone. Soon methadone was 
being used as an agent for detoxifying opioid addicts (Isbell and 

3 
Vogel, 1949). In these initial studies, methadone would be 
substituted for the opioid of abuse, and gradually tapered over a 7 to 
10 day period (Isbell and Vogel, 1949). 
Since the work of Isbell and Vogel in 1949, investigators have 
conducted many studies examining the efficacy of both inpatient and 
outpatient methadone detoxification. In their study comparing the 
cost and effectiveness of hospital versus outpatient detoxification, 
Wilson and his collegues reviewed previous detoxification studies 
using methadone (Wilson et al, 1975). In these studies, methadone 
was administered over time periods ranging from 2 weeks to 11 
months on both an inpatient and outpatient basis. Only 3% to 25% of 
patients were able to successfully complete detoxification. Follow-up 
of those patients further demonstrated that only 7% to 19% of 
patients who had been successfully withdrawn remained drug-free 6 
months after treatment (Wilson et al, 1975). 
Wilson's own study used a 10 day methadone regimen to detoxify 
40 heroin addicts, 10 in the hospital, and 30 in an outpatient setting 
(Wilson et al, 1975). One inpatient (10%) and 6 outpatients (20%) 
completed the detoxification. No inpatients (0%) and only 2 
outpatients (7%) remained drug-free 2 months after the 
detoxification was complete. The authors concluded that there was 
little benefit from either treatment approach, but that outpatient 
therapy was no less successful than inpatient. Outpatient trials 
employing 7 day and 90 day protocols demonstrated successful 
detoxification rates of 32% and 13%, respectively (Silsby and 
Tennant, 1974; Wilson et al, 1974). Six months following the 
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detoxification, 9.5% of those from the 7 day study and none of those 
from the 90 day study were drug-free. 
Senay, Dorus, and Showalter examined the 21 day methadone 
detoxification recommended by the Food and Drug Administration 
and compared it to an 84 day methadone detoxification under 
double-blind conditions (Senay et al, 1981). They found that 4 of 32 
(13%) patients completed the 21 day detoxification; however, none of 
these patients completed the full 90 day protocol. Five of 36 (14%) 
patients completed the 84 day detoxification and went on to 
complete the full 90 day protocol. All of these patients had remained 
drug-free in the follow-up period of 12 months or less (mean = 4.1 
months). They concluded that although the percentage of patients 
remaining drug-free was not large in either group, the more gradual 
84 day schedule increased the probability that patients would 
remain in treatment, without increasing their chances of becoming 
severely dependent on methadone (Senay et al, 1981). 
The concern that short term management of opioid withdrawal 
with methadone might lead to long term dependence on this agent 
was not unfounded. Methadone maintenance programs were initially 
established to ensure a "stable addiction" for patients, obviating the 
need for heroin as well as the criminal activity often necessary to 
support heroin use (Dole and Nyswander, 1967; Bowden and Maddux, 
1972). Orally administered methadone at a certain dose level does 
not appear to have a euphoric effect, but induces a marked, slowly 
developing tolerance to all opiate-like drugs, including methadone 
itself (Jaffe and Martin, 1985). As a result, the patient cannot feel 
the euphoric effect of ordinary doses of other narcotics such as 
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heroin or morphine. Methadone maintenance stabilizes the patient's 
a physiologic dependence, affording him the opportunity to modify 
his life in other areas: to achieve some stability in his family and 
other interpersonal relationships and to move away from 
involvement with heroin users and the subculture such use 
engenders. Although methadone maintenance has achieved a certain 
amount of success in moving the addict toward socially productive 
behavior, it has problems associated with its use (Szara and Bunney, 
1981). Because it is an opioid agonist with addictive potential, 
diversion to illegal channels is one of these problems. In addition, 
once on methadone maintenance, it has been difficult for the patient 
to achieve abstinence from methadone, an important goal of 
treatment. 
Kleber's review of studies examining detoxification from 
methadone maintenance demonstrates varying success rates (Kleber, 
1977). Successful detoxification of those felt "appropriate for 
detoxification," that is, those in good standing who were not being 
discharged from the program, ranged from 8% to 53% (Kleber, 1977). 
Relapse even after successful detoxification was considerable with 
only 20% to 33% of patients drug-free in a follow-up period of less 
than two years. One study has demonstrated quite successful 
withdrawal and follow-up statistics. Riordan and colleagues 
reported on 59 patients on methadone maintenance who were in 
good standing and underwent voluntary withdrawal (Riordan et al, 
1976). Of this group, 49 (84%) successfully completed detoxification. 
Of the 38 individuals followed-up at time periods ranging from 6 to 
44 months after detoxification, 26 (68%) had remained drug-free. 
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Despite these more optimistic results, investigators have 
continued to search for methods of detoxification that were more 
rapid and effective than methadone, without using opioid agonists or 
other addictive substances. Their efforts were facilitated by 
discoveries leading to a better understanding of the 
neuropharmacology of opioid dependence and withdrawal. Chronic 
administration of opioids produces profound effects on endogenous 
opioid function and noradrenergic activity in the central nervous 
system (Korf et al, 1974; Hollt et al, 1978; Herz et al, 1978; Przelocki 
et al, 1979). Although long term opioid administration does not 
appear to alter enkephalin levels, it does decrease endorphin 
synthesis as well as functional sensitivity to opioid agonists (Herz et 
al, 1978; Przelocki et al, 1979). In addition, studies of the brain's 
major noradrenergic nucleus, the locus coeruleus (LC), demonstrated 
that the prototype opiate morphine causes a marked reduction in LC 
neuronal firing rate (Korf et al, 1974). This decrease in LC activity 
and norepinephrine release is followed by a reciprocal increase in 
alpha-2 and beta adrenergic receptors in areas receiving LC 
projections (Llorens et al, 1978; Hamburg and Tallman, 1981). These 
data suggest an important role for the LC in opioid dependence 
withdrawal: some of the effects of opioids might be mediated 
through a decrease in LC activity and noradrenergic release. The 
discovery of specific opioid receptors in the brain (Hughes, 1975), 
with a high concentration located in the LC (Pert et al, 1975) was 
further evidence supporting such a mechanism. 
Studies in rodents and primates provided additional data 
implicating the neurotransmitter norepinephrine in opioid 
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dependence and withdrawal (Redmond, 1977; Cedarbaum and 
Aghajanian, 1977; Svensson et al, 1975; Meyer and Sparber, 1976). 
Gunne had previously shown that total brain norepinephrine 
decreased during opioid withdrawal suggesting that withdrawal was 
associated with increased norepinephrine release (Gunne, 1959). 
Cedarbaum and his colleagues found that an intravenous dose of the 
alpha-2 adrenergic agonist clonidine inhibited the spontaneous firing 
of brain norepinephrine-containing neurons in the LC by acting 
directly on the noradrenergic receptors located on those neurons 
(Cedarbaum and Aghajanian, 1977). Based on this knowledge 
clinicians have tried to modify opioid euphoria and withdrawal by 
giving drugs which modify these neurotransmitters. The beta 
adrenergic antagonist propranolol (Grosz, 1972), alpha adrenergic 
antagonists (Davis and Smith, 1973), and noradrenergic synthesis 
inhibitors (Davis and Smith, 1973) all have effects on opioid 
withdrawal. None of these agents has been shown to be as effective 
in alleviating the discomfort of withdrawal as the alpha-2 adrenergic 
agonist clonidine. 
In 1978, Clonidine hydrochloride was used by Gold to successfully 
block acute opiate withdrawal symptoms in 11 patients abruptly 
withdrawn from methadone maintenance (Gold et al, 1978a). 
Patients were given clonidine 36 hours after their last methadone 
dose (range = 15-50 mg methadone), when they all had objective 
signs of opioid withdrawal. All patients experienced relief of 
abstinence signs and symptoms for 4 to 6 hours after receiving a 5 
Mg per kg dose of clonidine. In a subsequent study, clonidine 
enabled 10 of 10 (100%) patients to successfully withdraw from 
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methadone (Gold et al, 1978b). This technique permitted patients to 
detoxify from methadone in less than 2 weeks with fewer symptoms 
than they would experience during the usual 4-6 month methadone 
detoxification. 
It was soon after this clinical success that Aghajanian, using single 
neuronal recording techniques and microiontophoresis, reported his 
investigation of the mechanism of clonidine as well as of the role of 
the LC in opioid withdrawal (Aghajanian, 1978). He found that 
endogenous and exogenous opioids decrease LC firing rates and that 
the opioid antagonist naloxone reversed this suppression of the LC. 
He observed that chronic opioid administration produced tolerance of 
the LC neurons to opioid suppression. Naloxone precipitated 
withdrawal produced the predicted noradrenergic hyperactivity 
which was reversible with clonidine. Furthermore, naloxone 
administration overrode morphine's suppression of the LC, but was 
unable to override clonidine's suppression of LC firing. He concluded 
that the LC is under the dual contol of opioid and alpha-2 adrenergic 
receptors. Opioid withdrawal produces central noradrenergic 
hyperactivity through disinhibition of the LC. This noradrenergic 
hyperactivity can be blocked by the alpha-2 adrenergic agonist 
clonidine through its action at receptors distinct from the opioid 
receptors to which morphine binds. 
Subsequent studies have demonstrated that clonidine does not 
alleviate withdrawal solely through its inhibition of noradrenergic 
firing. Lesions of noradrenergic neurons do not reduce clonidine's 
ability to attenuate behavioral signs of withdrawal (Britton et al, 
1984). The amygdala (Freedman and Aghajanian, 1986), spinal cord 
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(Franz et al, 1982), and forebrain (Matsui and Yamamoto, 1984) have 
all been proposed as other areas of clonidine’s activity in opiate 
withdrawal. 
Since the initial studies by Gold (Gold et al, 1978a; Gold et 
al; 1978b, Gold et al, 1980), other investigators have demonstrated 
clonidine's ability to ameliorate the abstinence syndrome in patients 
previously maintained on methadone with success rates of 80% to 
90% (Uhde et al,1980; Kleber et al, 1980; Charney et al, 1981). In 
double blind, placebo controlled studies, clonidine has proven itself 
more effective than placebo (Gold et al, 1978b) and as effective as a 
20 day methadone taper (Kleber et al, 1985; Washton and Resnick, 
1981) in alleviating the signs and symptoms of methadone 
withdrawal. Although it was recommended that shorter acting 
narcotics be withdrawn in less than a week using clonidine (Kleber et 
al., 1980), no inpatient studies and very few outpatient studies had 
examined clonidine's efficacy in detoxification from these agents. 
Early attempts at outpatient detoxification using clonidine were 
less successful. In the first double-blind study comparing clonidine 
and methadone in an outpatient setting, 31% of patients receiving 
clonidine were successfully detoxified from methadone maintenance 
compared to the 46% of patients undergoing rapid methadone taper 
(Washton and Resnick, 1980). In a subsequent study by the same 
investigators, 31 of 39 (80%) methadone patients and 4 of 11 (36%) 
heroin users were successfully detoxified using clonidine, for an 
overall success rate of 70% (Washton and Resnick, 1980). In this 
same study, a sub-group of methadone patients was detoxified using 
clonidine in conjunction with gradual methadone dose reductions. 
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Ten of 20 (50%) patients were successfully withdrawn in this 
manner. Kleber and colleagues also assessed clonidine detoxification 
under double-blind conditions (Kleber et al, 1985). Of 49 methadone 
patients whose dose had been lowered to 20 mg, 25 were detoxified 
using methadone tapered at 1 mg decrements, and 24 by abrupt 
substitution with clonidine. They found that 9 of 23 (39%) in the 
methadone group and 10 of 24 (42%) in the clonidine group achieved 
successful detoxification, with one third of the patients successfully 
detoxified in both groups maintaining abstinence over the 
subsequent six months. These success rates of outpatient clonidine 
detoxification contrasted sharply with the 80% to 90% success rate of 
clonidine inpatient detoxification. 
Outpatient detoxification using clonidine involves difficulties that 
do not arise in an inpatient trial. First, potential clonidine side 
effects such as hypotension and sedation are more difficult to 
managed on an outpatient basis. In an inpatient setting, increased 
clonidine doses can be used because of the increased capacity to 
monitor side effects. For this reason, clonidine doses given to 
outpatients at Yale have been tapered or held if diastolic blood 
pressure dropped below 55, or systolic pressures were lower than 
85. Second, the temptation and opportunity to deal with discomfort 
by using narcotics is greater in outpatient settings where these 
agents are more readily available. However, despite these 
drawbacks of outpatient detoxification, there are compelling reasons 
for improving the efficacy of outpatient therapy: many patients are 
unable to be hospitalized for the time required by inpatient 
programs; many programs do not have an inpatient detoxification 

unit available; finally, inpatient treatment places more stress on 
limited medical resources. 
In addition to the problem of lower success rates in the outpatient 
setting, both clonidine and methadone therapy failed to shorten the 
time required for withdrawal. This was especially problematic in the 
outpatient setting, for a long duration of mild withdrawal symptoms 
affords outpatients a greater opportunity to resume opioid use. 
Previous efforts to shorten the withdrawal period by Blachley and 
his colleagues demonstrated that the pure opiate antagonist naloxone 
given parenterally to opiate dependent patients precipitated 
withdrawal and shortened the period required for this withdrawal 
(Blachley et al, 1975). They noted that the intensity of this 
precipitated withdrawal decreased with successive doses of naloxone 
with the withdrawal period complete in 1 or 2 days. Despite their 
claims that patients experienced less total discomfort than that 
experienced with longer, but more gradual withdrawal, this means of 
detoxification was never practiced extensively. Other groups have 
tried this technique (Kurland and McCabe, 1976; Resnick et al, 1977), 
but were never able to satisfactorily ameliorate the intensified 
withdrawal symptoms with symptomatic medication. 
Based on data that clonidine had been noted to block naloxone 
induced morphine withdrawal (Meyer and Sparber, 1976), Riordan 
and Kleber combined clonidine and naloxone therapy to successfully 
withdraw 3 heroin users and 1 methadone patient over a 4 day 
period. This was accomplished in a three stage procedure. On day 1, 
opioids were withheld and patients received only clonidine; on days 
2 and 3, patients received both clonidine and naloxone; on day 4, 
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patients received clonidine and a single evening dose of naloxone to 
determine whether they had any persistent opioid tolerance (Riordan 
and Kleber, 1980). All 4 (100%) inpatients were successfully 
detoxified using this method. 
Naloxone (N-allylnoroxymorphone) is a pure opiate antagonist 
effective only when administered parenterally (Eddy and May, 
1973). Although naloxone produces effective blockade of morphine, 
this blockade is short lasting and decays completely over a 4 hour 
period. One study has demonstrated naloxone's ability to attain 
effective blockade of morphine for nearly 24 hours; however, this 
required 3,000 mg per day of naloxone, a dangerously large dose of 
this agent (Zaks et al, 1971). This short half-life and parenteral route 
of administration severely limited the use of naloxone in the 
treatment of opioid dependency. 
In 1965, Blumberg and Dayton synthesized naltrexone (N- 
cyclopropyl-methylnoroxymorphone), an analogue of naloxone which 
was longer lasting and potent orally (Blumberg and Dayton, 1972). 
The principal pharmacologic action of naltrexone is that of an opioid 
antagonist. Naltrexone blocks the action of opioids by competitive 
binding at the opioid receptor to displace any opioids present as well 
as block the effects of subsequent opioid administration. To avoid 
the precipitation of the opioid abstinence syndrome, it is 
recommended that patients using short-acting opioids, such as heroin 
and morphine, await 7 days after their last use of that substance 
before initiating naltrexone therapy (Kleber et al, 1985a). 
Individuals using longer-acting opioids, such as methadone, are 
advised to wait 10 days before initiating naltrexone therapy. 

13 
However, the longer the interval before naltrexone is begun, the 
greater the chance that the addict will return to opioid use. Because 
of this, investigators have continued to search for treatment 
modalities which would both shorten the withdrawal syndrome as 
well as enable earlier naltrexone induction. 
Charney and his colleagues used clonidine and naltrexone in 
combination to provide a safe, effective, and rapid withdrawal for 
patients maintained on methadone (Charney, 1982). Over a 6 day 
period, 10 of 11 (91%) patients were able to withdraw completely 
from methadone therapy. This detoxification was also accomplished 
in two stages. On day 1, patients had their regular methadone 
maintenance dose held and received clonidine therapy alone. On 
days 2 and 6, patients received oral naltrexone therapy in addition to 
clonidine. The naltrexone was administered in increasingly higher 
doses until day 5 when maintenance levels (50 mg) were attained in 
a single daily dose. Clonidine doses had reached a maximum on 
days 2 and 3 ( 2.9 +/- 0.6 and 2.3 +/- 0.6, respectively) and were 
rapidly tapered on days 4 through 6. No one required clonidine 
therapy after day 6. Three of the 10 (30%) patients decided to 
continue on naltrexone maintenance therapy. In a follow-up period 
ranging from 4 months to one year, only 1 of the 10 patients had 
returned to opioid use. In an extension of this study, Charney 
examined a total of 40 methadone patients who were detoxified 
using combination clonidine and naltrexone therapy (Charney et al, 
1986). Fourteen (including the 11 from the previous study) were 
detoxified using the same two stage dosage regimen described above. 
Twenty-six were detoxified in a single stage procedure, eliminating 
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the first day of clonidine therapy alone. Patients in this group 
received both clonidine and naltrexone therapy on days 1 through 4 
of the study and attained naltrexone maintenance levels (50 mg) by 
day 4. For both groups, naltrexone doses were gradually increased 
from 1 mg to 50 mg over a 4 day period. Thirty-eight of 40 (95%) 
patients withdrew from opioids completely over the 4 or 5 day 
period. 
Combination clonidine and naltrexone therapy has also been 
proven effective in the outpatient setting. Over a 5 day period 
Kleber and colleagues successfully withdrew 12 of 14 (86%) heroin 
users from opioids while simultaneously initiating naltrexone 
therapy (Kleber et al, in press). This study was conducted using 
clonidine and naltrexone doses similar to those used in the previous 
inpatient study (Charney et al, 1982; Charney et al, 1986). An 
important difference was a naloxone challenge test (NCT) 
administered on the first day of the study. Unlike the patients in 
Charney's study who had been maintained on a known amount of 
methadone, patients in this study used illicit opiate preparations 
with inconstant opiate concentrations. The naloxone challenge test 
was used to establish opioid dependence in these patients as well as 
objectively quantify that dependence (Wang, 1974; Weisen; 1977; 
Wang 1982). This ensured that only opioid dependent individuals 
entered the detoxification, and that those who did received adequate 
initial clonidine doses. Of the 12 patients who successfully completed 
the 5 day detoxification and the week of naltrexone maintenance, 5 
(42%) remained in naltrexone maintenance one month later and 3 
others (25%) claimed to be completely drug free. 
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These studies demonstrate that combination clonidine and 
naltrexone therapy is able to speed the time course of opiate 
withdrawal without increasing symptomology (Charney et al, 1982; 
Charney et al, 1986; Kleber et al, in press). In addition, naltrexone 
and clonidine detoxification appears to equalize the time course of 
the heroin and methadone withdrawal syndromes (Kleber, in press). 
Naltrexone is thought to speed the process of withdrawal by rapidly 
reversing opioid-induced central noradrenergic hypersensitivity. 
Administration of naltrexone to opioid dependent animals rapidly 
reverses morphine-induced increases in the number of brain alpha-2 
and beta adrenergic binding sites (Hamburg and Tallman, 1981; 
Cedarbaum and Aghajanian, 1977). Clonidine is able to suppress the 
intensified noradrenergic discharge which naltrexone would 
otherwise produce, and in this manner alleviate withdrawal 
symptomatology. The clonidine naltrexone protocol appears to 
equalize the heroin and methadone withdrawal syndromes by 
displacing opioids from binding sites thereby eliminating the effects 
of opioid half-life on the time course of central noradrenergic 
normalization (Kleber in press). 
Outpatient clonidine and naltrexone detoxification is a safe and 
effective method of treating opiate withdrawal. This therapeutic 
combination also facilitates follow-up naltrexone maintenance 
therapy, effective treatment for the relapsing character of opioid 
dependence. Failure of previous outpatient clonidine detoxifications 
to match inpatient success rates may have been due largely to the 
greater temptation and opportunity to deal with discomfort by using 
opioids which are more available in the outpatient setting. The 
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addition of naltrexone therapy removes this temptation by producing 
opioid blockade early in detoxification. Comparable success rates of 
outpatient clonidine and naltrexone detoxification and inpatient 
clonidine detoxification support this hypothesis as well as the 
conclusion that combination clonidine and naltrexone therapy should 
be a more widely practiced treatment for opiate withdrawal. 
However, the doses of naltrexone used in the protocol are smaller 
than those available commercially. The purpose of this study was to 
develop an outpatient clonidine and naltrexone protocol using 
naltrexone doses available to all treatment programs. Although, the 
use of larger naltrexone doses risks precipitation of a more intense 
withdrawal and an outpatient setting may limit the amount of 
clonidine which may be necessary to ameliorate this withdrawal 
syndrome, outpatient detoxification is a desirable mode of treatment 
for both patients and physicians. 
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MATERIALS AND METHODS 
1. SUBJECTS 
The patient group included 18 heroin abusers, 10 men and 8 
women, treated at the Substance Abuse Treatment Unit of the 
Connecticut Mental Health Center, New Haven, Connecticut. As shown 
in table 1, mean age (+/- S.D.) was 30.0 years (+/- 4.1) and mean 
duration of opioid use was 8.4 years (+/- 6.3). Types of opiates 
abused included: intravenous heroin (n=16), intranasal heroin (n=3), 
intravenous hydromorphone (Dilaudid) (n=2), intravenous 
methadone (n=l), oral oxycodone (Percocet) (n=l), and oral 
meperidine (Demerol) (n=l). Of note, 6 of the patients who were 
using intravenous heroin stated that they were using synthetic 
opiates (i.e. "Liberty," "Blue Thunder," etc.). Polydrug abuse 
included: intravenous cocaine (n=7), intranasal cocaine (n=2), 
marijuana (n=13), benzodiazepines (n=2), and alcohol abuse (n=4). 
Eleven patients had undergone prior substance abuse treatment 
including detoxification (n=8), methadone maintenance (n=3), and 
naltrexone maintenance (n=4). The mean naloxone challenge test 
score on the Wang scale (Wang, 1982) was 16.1 (+/-1.5). 
All patients participating in the study were in good health as 
evidenced by a physical examination, medical history, psychiatric 
screening interview, laboratory analysis, and ECG performed one 
week prior to the detoxification. Laboratory analysis included a CBC, 
LFT's, VDRL, Hepatitis screening, and urinalysis. In addition, any 
woman participating in the study received a Beta-HCG pregnancy 
test. Candidates were excluded from the study if they: 1) were 
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younger than 18 years or older than 45 years, 2) had a systolic blood 
pressure greater than 165 or a diastolic blood pressure greater than 
110, or were undergoing medical treatment for hypertension, 3) 
were receiving current treatment for other medical conditions 
requiring ongoing medication, 4) had been treated with tricyclic 
antidepressants, MAO inhibitors, or phenothiazines during the two 
weeks prior to participation, 5) were allergic to imidazoline drugs, 6) 
had a history of acute or chronic hepatitis, cardiac arrythmias, 
rheumatic fever, sinus bradycardia of less than 50 bpm, renal or 
metabolic disease, 7) had a history of a severe psychiatric disorder 
(e.g., major psychotic episode, schizophrenia, psychotic depression, 
bipolar affective disorders), or 8) were pregnant. (All women 
participating in the study had a negative Beta-HCG test within one 
week of the study.) 
2. TREATMENT SCHEDULE 
Patients were divided into two treatment cohorts. Patients 
referred to the Substance Abuse Treatment Unit for detoxification in 
the first half of the study underwent a 5 day detoxification. 
Detoxification time was then reduced to 4 days for all patients in the 
second half of the study. On day 1 patients in the first cohort 
underwent a naloxone challenge test followed by clonidine therapy 
administered three times a day. On the subsequent 4 days patients 
received a combination of clonidine and naltrexone therapy. 
Naltrexone was given in a single morning dose on days 2 through 5. 
Supplementary clonidine doses were available to patients on days 2 
and 3. For those patients in the second half of the study days 1 and 
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2 of the detoxification were combined. On day 1 patients in the 
second cohort also underwent a naloxone challenge test followed by 
clonidine therapy administered three times a day. However, unlike 
the original cohort, these patients received their first naltrexone dose 
in the afternoon of their first day. All subsequent naltrexone doses 
were advanced one day. Both protocols are summarized in Table 2. 
Patients came to clinic daily at 8-9 am to receive medication, 
answer questionaires, and have their blood pressure monitored. 
Patients in the first cohort were required to remain in clinic from 
8:30 am to 3:00 pm on the first three days of the study so that their 
withdrawal symptoms could be followed, blood pressure and heart 
rate monitored, and clonidine doses adjusted accordingly. Patients in 
this group were not permitted to work on the second and third days, 
and were not permitted to drive on the first three days. They were 
asked to remain at home these first three evenings. In order to 
minimize orthostatic blood pressure effects, patients were instructed 
to sit when urinating and to avoid hot showers. For the second 
cohort these restrictions only applied to the first two days. When a 
"significant other" picked the patient up at the conclusion of the first 
day of the study, the study was explained to them and they were 
asked to sign the patient's consent form. An investigator was on call 
each evening to respond to questions. 
While in clinic both groups had their blood pressure monitored 
immediately before, 60 minutes after, and 120 minutes after each 
clonidine dose. Subjective and objective abstinence rating scales 
were filled out at these times as well as immediately before and 60 
minutes after the patient's daily naltrexone dose. Patients took a 
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prescribed evening dose of clonidine home with them as well as 0.1 
to 0.3 mg for "prn" doses. They were asked to fill out a subjective 
abstinence rating scale at 8:00 pm before taking their evening dose 
of clonidine and also to return extra pills the following morning. 
On days 1, 2 and 3 additional clonidine doses were given one hour 
following daily naltrexone doses if the patient had 5 or more of the 
17 signs and symptoms of withdrawal included in our abstinence 
rating scale. Clonidine doses were tapered or held, if standing 
systolic blood pressure was less than 80 mm Hg, if diastolic pressure 
was less than 60 mm Hg, or if patients complained of orthostatic 
symptoms. 
Naltrexone therapy was begun on day 2 for the patients in the 
first cohort and was administered at 9:00 am (30 minutes following 
the am clonidine dose). This initial dose was 12.5 mg or one fourth 
of the 50 mg scored naltrexone tablet (Trexan). This dose was 
increased to 25 mg on day 3, 50 mg on day 4, and 100 mg on day 5 
(usually a Friday). All naltrexone doses were administered at 9:00 
am. Patients then entered a naltrexone maintenance program the 
following Monday to continue their naltrexone therapy. 
Patients in the second cohort began their naltrexone on the first 
day of the protocol, receiving 12.5 mg of naltrexone at 1:30 pm (30 
minutes following their second clonidine dose and two to three hours 
following their NCT). They then received 25 mg at 9:00 am on day 2, 
50 mg on day 3, and 50 or 100 mg on day 4 depending on the day of 
week and what day they would enter the naltrexone maintenance 
program (Tuesday or Thursday patients received 50 mg; Monday, 
Wednesday, or Friday patients received 100 mg). 
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Patients were given chloral hydrate, 1 gm, as indicated for 
insomnia. For patients who did not respond to chloral hydrate, or 
who experienced muscular aching not relieved by clonidine, 
flurazepam 30 mg or diazepam 10 mg was prescribed in place of 
chloral hydrate. 
Urine samples were obtained on days 1, 3, and 5 from the first 
cohort and days 1, 3, and 4 from the second cohort. These were 
analyzed to evaluate any use of illicit drugs. 
3. NALOXONE CHALLENGE TEST 
The degree of a street addict's opiate dependence is difficult to 
determine because of unreliable histories and variable opiate 
concentrations found in illicit preparations. Through the naloxone 
challenge test we were able to establish opiate dependence as well as 
determine the degree of that dependence. We could then more 
reliably estimate initial clonidine doses and ensure a more 
comfortable detoxification. The naloxone challenge test was 
described by Wang in 1974 (Wang, 1974) and modified in 1977 and 
1982 (Weisen, 1977; Wang 1982). It consists of an intramuscular 
injection of 0.8mg naloxone followed by scoring of withdrawal 
symptoms at 10, 20, and 30 minutes. The Wang rating scale scores 
objective symptoms of withdrawal, giving more weight to symptoms 
if they appear more rapidly (See Table 3). Patients received 
clonidine after 10 or 20 minutes if their predicted score on Wang's 
36 point scale was greater than 9 at those times, otherwise they 
received clonidine at 30 minutes. An additional clonidine dose was 
given one hour later if their Wang abstinence score remained above 

5. Patients without symptoms at 10 minutes received an additional 
0.8 mg naloxone intramuscularly. Individuals whose score was less 
than 2 at 30 minutes after their second injection of naloxone (total of 
1.6 mg naloxone), were told that they did not have a clinically 
recognizable acute withdrawal syndrome, were dropped from the 
study, and were referred to a naltrexone maintenance program. Day 
1 clonidine doses, based on naloxone challenge test scores, are listed 
in Table 4. 
4. INSTRUMENTS 
Throughout the course of the detoxification, patients' objective 
and subjective symptoms of withdrawal were closely monitored 
using withdrawal scales from previous detoxification studies at the 
Connecticut Mental Health Center (Charney, 1981; Charney, 1982; 
Kleber, in press ). Every morning prior to medications, patients were 
asked to complete a withdrawal line, craving line, opiate withdrawal 
scale (self-rated), and a self-rated visual analog scale. The 
withdrawal line is a 100 millimeter long horizontal line that 
functions as an analogue scale. The left end of the line is marked "0 
- no withdrawal" and the right end is marked "100 - severe 
withdrawal." In addition, patients completed this scale before and 
60 minutes following their daily naltrexone dose. Similar to the 
withdrawal line, the craving line is a 100 millimeter horizontal line 
with its left end marked "0 - no craving" and the right end marked 
"100 - severe craving." The opiate withdrawal symptom checklist is 
a self-rated analogue scale containing 38 statements pertaining to 
symptoms of opiate withdrawal (e.g., "My bones and joints have been 
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aching") (Haertzen and Meketon, 1968). Patients rated each of these 
statements on a 1 (not at all) to 4 (very much) point scale. The self- 
rated visual analogue scale contains five symptoms (energy, 
nervousness, irritability, uninvolvement, and unpleasantness) which 
patients rated on a l(low) to 7(high) point scale. 
In addition to the rating scales completed every morning by the 
patients, observer-rated abstinence rating scale (ARS) were 
completed for each patient at specific time intervals throughout each 
day. The ARS monitors 17 signs and symptoms associated with opioid 
withdrawal (see Table 5). On the first day of the detoxification, the 
ARS was measured before the NCT, immediately after the NCT but 
before any clonidine was given, at 30, 60 and 120 minutes after the 
initial clonidine dose, and immediately before the 2:00 pm clonidine 
dose. On subsequent days, the ARS was measured in the morning 
prior to any medication, before the daily naltrexone dose, 60 minutes 






1. Acute Detoxification 
Eighteen patients underwent a naloxone challenge test (NCT). One 
had a negative challenge test (Wang score below 2 after a total 
naloxone dose of 1.6 mg) and was dropped from the study. Of the 
seventeen patients who entered the protocol, nine began the 5 day 
detoxification, and eight began the 4 day detoxification. Of the nine 
patients who entered the 5 day study, eight successfully completed 
detoxification (89%) and were discharged on maintenance doses of 
naltrexone. The patient who failed to complete the study had a peak 
NCT score of 15. This score was comparable to the mean peak NCT 
score for the patients completing the protocol (15.5 +/-3.3). 
Throughout the first day she complained of considerable discomfort 
from leg cramps unrelieved by clonidine. These were relieved in the 
afternoon of the first day by warm soaks. Despite this relief, the 
patient failed to return the morning of the second day. She returned 
to the Substance Abuse Treatment Unit and was subsequently 
detoxified as an inpatient with methadone. She then entered the 
naltrexone maintenance program for a brief period before leaving to 
enroll in methadone maintenance. 
Of the eight patients who entered the 4 day study, six successfully 
completed detoxification (75%) and were discharged on maintenance 
doses of naltrexone. The two patients who failed to complete the 
study were similar in that they both experienced less discomfort 
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than most patients, but failed to return for the fourth and final day 
of the protocol. The first had a NCT score of 16 at 10 minutes, 
comparable to the mean peak NCT score (+/- S.D.) of 17.0 (+/- 3.3) for 
the patients completing the protocol. This patient returned to clinic 
on the following day (day 5) stating that he had used intravenous 
heroin the preceding evening (confirmed by urine toxicology screen). 
Repeated efforts to restart him on naltrexone were unsuccessful. The 
second patient had a peak NCT score of 9 after 1.6 mg of naloxone. 
She never returned to the clinic despite repeated efforts by phone to 
reestablish contact. Of note, because these patients had completed 3 
days of the 4 day protocol, they had achieved a maintenance dose of 
naltrexone (50 mg/day). 
2. Follow-up 
Six of the eight patients (75%) completing the 5 day protocol 
began naltrexone maintenance the week following their 
detoxification. Both of the patients who had failed to enter 
naltrexone maintenance had moved out of the area that same week. 
Arrangements had been made for one of these patients to enter 
naltrexone maintenance in the area to which she was moving; 
however, she failed to report to that naltrexone maintenance 
program. One month after completing the protocol, five of these six 
patients remained in naltrexone maintenance. 
Four of the six patients (67%) completing the 4 day protocol began 
naltrexone maintenance the week following their detoxification. One 
month after completing the protocol all four of these patients 
remained in naltrexone maintenance. The two patients who failed to 
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enter a naltrexone maintenance program were again using opioids 
one month after completing the detoxification. 
B. RESPONSE TO OPIOID ANTAGONISTS (NALOXONE AND 
NALTREXONE) 
Opioid antagonists precipitated significant withdrawal symptoms, 
but symptoms were adequately relieved by clonidine. The mean 
Wang score for all patients following the NCT was 16.1 (+/- 5.1), 
corresponding to a methadone dose requirement of 40 mg/day by 
Wang's criteria (Wang 1982). On day 1, both cohorts responded well 
to clonidine given at 10 or 20 minutes (depending on the patient's 
NCT score) following the intramuscular naloxone. By 30 minutes 
after receiving clonidine patients in both cohorts had experienced 
symptom relief as demonstrated by the abstinence rating scale 
(ARS). Two hours after the first oral dose of clonidine, patients in 
both cohorts had lower ARS scores than prior to the NCT. This 
reflects both the efficacy of clonidine in relieving symptoms as well 
as the half-life of naloxone (approximately 60 minutes). 
Patients in cohort 2 received their first dose of naltrexone 
(12.5mg) on the first day, two hours after receiving their initial dose 
of clonidine. Of note, only two patients (NCT scores= 20 and 6) 
experienced an increase in their ARS scores 60 minutes after this 
naltrexone dose. Even with the increase, each of these patients' ARS 
scores were less than 5. 
Patients in the first cohort received their first dose of naltrexone 
(12.5mg) on the second day, 30 minutes following their morning dose 
of clonidine. Only one patient (NCT score=16) experienced an 
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increase in symptoms, and these symptoms responded well to a 
supplementary clonidine dose. 
Both groups of patients experienced a rise in their ARS score the 
morning of their second day before any medication had been given. 
This responded well to the morning dose of clonidine, and probably 
represented the time lag between their 8pm and 9am dose of 
clonidine. Although many had taken 0.1-0.2mg of clonidine for 
discomfort during the night, this was still less than their regular 
clonidine dose. This morning pre-medication rise in ARS score was 
also experienced on day 3 by the patients in the 5 day detoxification. 
This was not experienced on days 3 or 4 by those in the 4 day 
detoxification, when they were receiving a maintenance dose of 
naltrexone (50mg and 50 to lOOmg, respectively). 
Unlike patients in the 4 day detoxification, those in the 5 day 
detoxification experienced transient rises in ARS on days 3 and 4, 
sixty minutes following their daily naltrexone dose. When patients' 
ARS exceeded a score of 5, they were given supplementary doses of 
clonidine and responded well to them. On day 5, all patients 
received 100 tol50 mg naltrexone without any symptoms. 
C. ABSTINENCE SYMPTOM RELIEF 
The treatment regimen effectively suppressed signs and 
symptoms of withdrawal. On no day was the mean number of signs 
and symptoms greater than 5 out of the 17 included in the 
abstinence rating scale (Figure 1). Persistent symptoms were 
anxiety, restlessness, insomnia, muscle aches, and "yen" for sleep. 
Often the signs and symptoms reported were mild in nature. 
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Through the course of the detoxification patients experienced 
significant symptom relief (5 day detoxification F(5,47)=6.6, pc.005; 4 
day detoxification F(4,29)=4.5, pc.01). There was no significant 
difference between the two groups (treatment F(l,63)=.3). There 
was a significant correlation between NCT score and mean ARS scores 
for patients in both groups on days 1 and 2 (Day 1, p c .05; Day 2, p c 
.01), which accounted for 30% to 45% of the variance in ARS. 
Patient ratings of withdrawal (Figure 2), indicated that the 
withdrawal process was relatively comfortable for the majority of 
patients. On this scale, the mean withdrawal line for those in the 4 
day detoxification was significantly higher than for those in the 5 
day (treatment F=6.3, pc.025). This difference was also shown on the 
opiate withdrawal scale (treatment F= 16.5, pc.005), another patient 
rated analogue scale shown in Figure 3. However, elimination of 
baseline differences by examination of the percentage change from 
day 1 of these withdrawal scale scores demonstrates no difference 
between the two treatments (Figure 3B). Craving lines (Figure 4) and 
patient rated analogue scales (Table 6) for both detoxification groups 
did not differ or change significantly over the course of the 
detoxifications. 
D. BLOOD PRESSURE CHANGES AND SIDE EFFECTS OF CLONIDINE 
The effects of the clonidine-naltrexone treatment on standing 
systolic and diasolic blood pressure and standing and supine heart 
rate are summarized in figures 5 through 8. As shown in Figure 5, 
clonidine significantly lowered systolic blood pressure for both 
groups (4 day detoxification F(5,35)= 6.0, pc .005; 5 day 
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detoxification F(6,55)=2.6, p<.05). On days 1 through 4 for those in 
the 5 day detoxification, and days 1 through 3 for those in the 4 day 
detoxification, systolic blood pressure differed significantly from the 
"initial" values (paired t test pc.01). The decrease in systolic blood 
pressure for those in the 4 day detoxification was not significantly 
greater than that for those in the 5 day detoxification (F=2.6, pc.25). 
Clonidine significantly lowered the diastolic blood pressure (Figure 6) 
of the patients in the 4 day protocol (F(5,35)=5.4, pc.005); however, 
the diastolic blood pressure of patients in the 5 day protocol was not 
significantly lowered (F(6,55)= 2.1, pc.l). Diastolic blood pressure on 
days 1 through 4 for patients in both detoxification groups differed 
significantly from "initial" values (paired t test pc.005 to pc.025). As 
shown in figures 7 and 8, clonidine did not significantly alter 
standing and supine heart rates of patients in the 4 day 
detoxification (standing F(5,35)=.6; supine F(5,35)=1.9). The standing 
heart rate (figure 7) of patients in the 5 day detoxification was not 
significantly decreased by clonidine (F(6,55)=.8); however, supine 
heart rate (Figure 8) was significantly decreased by clonidine 
(F(6,55)=2.7, pc.05). This is probably reflective of the bradycardic 
effects that clonidine may produce at rest which are overridden 
when standing or exercising (Pettinger, 1975). There were no 
syncopal episodes during the course of treatment; however, most 
patients reported dizziness on standing during days 2 and 3. There 
was no significant difference between the groups in mean total 
clonidine required per day. In both groups, patients with NCT scores 
greater than 20 did not have significantly larger decreases in blood 
pressure or heart rate than did patients with NCT less than 20. 
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Other commonly reported side effects from clonidine were dry 
mouth and sedation. 
E. PATIENT COMPLIANCE 
Patients took evening clonidine doses as instructed and returned 
unused clonidine in the morning when they reported to clinic. One 
patient in the 5 day detoxification used intravenous heroin on the 
evening of the first day. She was allowed to continue in the protocol 
and experienced no adverse effects when she received the full 
scheduled dose of naltrexone on the second day. Two patients in the 
4 day detoxification used intravenous cocaine on the afternoon of the 





1. CLINICAL OUTCOME 
The clonidine-naltrexone outpatient detoxification enabled 14 of 
17 (82%) opioid dependent patients to completely withdraw from 
short acting opioids within a 4 or 5 day period and simultaneously 
begin naltrexone maintenance. This success rate is higher than that 
achieved using either of the standard methods of outpatient 
detoxification: gradual methadone taper (13% to 46 %) (Wilson, 1974; 
Wilson, 1975; Silsby, 1974; Senay and Dorus, 1981; Washton and 
Resnick, 1981), or clonidine alone (31% to 40%) (Washton and 
Resnick, 1981; Kleber, 1985). The results of this study are 
comparable to the success rate achieved in a similar outpatient 
regimen enabling 12 of 14 (86%) heroin users to withdraw from 
opioids in 5 days (Kleber, in press). Although the earlier study also 
enabled a high percentage of patients to withdraw from short acting 
opioids and attain maintenance levels of naltrexone on an outpatient 
basis, the present 5 or 4 day detoxification allowed a more rapid 
withdrawal with a simplified, single-dose-per-day naltrexone 
regimen. Such a regimen significantly reduced the period of time 
patients spent in clinic without significantly increasing daily 
clonidine doses or changes in blood pressure. 
Comparison of the two detoxification groups in this study 
demonstrate that initiating naltrexone therapy sooner significantly 
shortened the withdrawal syndrome without increasing observer- 
rated symptomatology. Patients in the 5 day detoxification began 
naltrexone therapy on the second day of the detoxification with 
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maintenance levels (50 mg) achieved by the fourth day. Patients in 
the 4 day group began naltrexone therapy on the first day of the 
detoxification and achieved maintenance levels by the third day, 
forty-eight hours after their last opioid use. Comparison of the 
abstinence rating curves of both groups (Figure 1) shows almost 
complete abstinence relief in the third day of the protocol for those 
in the 4 day study, a level achieved on the fourth day by those in the 
5 day study. Another advantage of receiving naltrexone on the first 
rather than second day of detoxification was that patients were less 
likely to use opioids in the early stages of the detoxification, before 
complete opioid blockade had been achieved. 
Although there was no significant difference between the two 
groups in observer-rated withdrawal symptomatology, there was a 
significant difference in patient-rated symptomatology (Figures 2 
and 3). Because there were significant baseline differences between 
the two groups on both these withdrawal scales, the baseline 
differences were adjusted by examining percentage change from day 
1 (Figures 2B and 3B). With this adjustment, no significant 
difference was found between the treatments. 
The clonidine and naltrexone combination worked well in the 
outpatient setting. Signs of opioid withdrawal were rarely seen, and 
patients reported mild withdrawal symptoms. The symptoms not 
relieved by clonidine were primarily restlessness, muscle aches, and 
insomnia, which were more likely to persist in patients with higher 
NCT scores. Those in the 4 day study with persistent restlessness or 
muscle aches were prescribed diazepam 10 mg twice a day on days 1 
and 2. They experienced significant relief from this intervention. 
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Clonidine significantly lowered standing blood pressures on the first 
three days of the study for each group; however, no clinical problems 
resulted from this and patients were not working or driving on these 
days. Many patients in both groups requested that clonidine doses 
be held by the fourth day of the protocol to alleviate the sedation 
that they were experiencing. At this time in the study, clonidine 
doses could be quickly tapered without the consequence of 
withdrawal symptoms arising or rebound hypertension occurring 
(Pettinger, 1975; Pettinger, 1980; Hansson, 1973). 
Limitations of outpatient treatment emerged. Of the three 
patients who withdrew from the study, two had already attained 
maintenance levels of naltrexone. One of these two patients was 
relatively asymptomatic, but failed to return to clinic the morning of 
the fourth and final day. The following week he returned to the 
outpatient clinic, but never began naltrexone maintenance. His 
failure to complete the detoxification despite achieving maintenance 
naltrexone levels with mild withdrawal symptomatology probably 
reflects the ambivalence many addicts have about remaining drug- 
free; it is unclear whether inpatient detoxification would have been 
more successful in detoxifying this patient. The other patient had 
the lowest NCT score, with a maximum of 8, 10 minutes after 
receiving her second 0.8 mg dose of naloxone (total naloxone dose = 
1.6 mg). She had been dependent on oral oxycodone and 
experienced considerable gastrointestinal cramps on the second and 
third days of the protocol, which were unrelieved by clonidine. The 
anticholinergic, antispasmodic agent atropine 0.4 mg was prescribed 
three times a day in an effort to counteract the rebound increase in 
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gastrointestinal activity probably responsible for her discomfort 
(Lord, 1977; Burks, 1976); however, this was also ineffective. 
Although somewhat milder, the abstinence syndrome associated with 
oxycodone resembles that of morphine and lasts approximately 7 
days (Charney and Kleber, 1980). Gastrointestinal cramping may 
have been more of a problem for this patient because the oral route 
of her opioid administration would sensitize her gastrointestinal 
opioid receptors to a greater degree than intravenous or intranasal 
routes. This would be a phenomenon unique to oxycodone, since 
detoxification from oral methadone does not produce such 
gastrointestinal discomfort even when withdrawal is precipitated 
using the clonidine naltrexone combination (Charney, 1982). In a 
previous study using clonidine to detoxify a patient addicted to 
oxycodone, the patient did not complain of any gastrointestinal 
discomfort throughout the detoxification (Charney and Kleber, 1980). 
It is possible that the addition of naltrexone, an oral opioid 
antagonist, so early in the detoxification of these patients may 
precipitate significant gastrointestinal symptoms through its 
antagonistic action directly on their sensitized gastrointestinal opioid 
receptors. Clonidine therapy alone may be the detoxification of 
choice in oral oxycodone users followed by institution of naltrexone 
maintenance when their gastrointestinal opioid receptors are not as 
sensitive to its effects. 
The third patient who did not complete the detoxification began 
the 5 day study but did not return after the first day. She had a NCT 
of 16, and experienced considerable muscle cramps in her legs 
throughout the first day, which were eventually relieved by warm 
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soaks. In later detoxifications, diazepam, 10 mg twice a day, was 
successful in alleviating persistent muscle cramps which some 
patients experienced. This lack of intervention may have affected 
her continued participation in the study. 
Unlike the previous clonidine-naltrexone outpatient 
detoxification, this protocol did not include a week of naltrexone 
therapy following the detoxification. Instead, patients continued 
naltrexone maintenance at one of the two naltrexone maintenance 
programs offered by the Substance Abuse Treatment Unit. Ten of 14 
(72%) patients who completed the detoxification returned for 
naltrexone maintenance. In the week following detoxification, 
patients had their blood pressures measured and signs and 
symptoms rated using the abstinence rating scale. Only two patients 
complained of symptoms sometimes associated with the stabilization 
period of naltrexone therapy (Hollister, 1981; Kleber and Kosten, 
1984). 
2. NALOXONE CHALLENGE TEST {NCT} 
The naloxone challenge test (NCT) established opioid dependence 
in patients requesting detoxification. One of the 18 (5.6%) patients 
who entered the study had a negative NCT, a rate less than the 15% 
to 34 % of negative naloxone challenges found in patients applying 
for methadone maintenance (Blachley, 1973, Wang, 1982). The NCT 
also served to guide initial clonidine doses by quantifying the degree 
of patients’ dependence. Day 1, 2, and 3 clonidine doses varied 
directly with NCT scores. Although NCT scores aided in the 
determination of clonidine doses, abstinence rating scale (ARS) 
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scores as well as blood pressure measurements ultimately 
determined how much clonidine patients would receive. This 
flexibility in clonidine doses ensured a safer and more effective 
detoxification. 
This study demonstrated a significant correlation between NCT 
and ARS scores for patients on the days 1 and 2 of the study (Day 1, 
p < .05; Day 2, p < .01). The NCT, a measurement of the degree of a 
patient's addiction, accounted for 30% to 45% of the variance in ARS 
scores on those days. 
3. MECHANISM OF ACTION OF CLONIDINE AND NALTREXONE IN 
OPIOID WITHDRAWAL 
Clonidine attenuates the opioid withdrawal syndrome by 
suppressing the rebound noradrenergic hyperactivity which occurs 
when chronic opioid administration ceases (Korf, 1974; Llorens, 1978; 
Maas, 1979). It accomplishes this by binding presynaptically to 
alpha-2 adrenergic receptors, mimicking feedback inhibition to the 
locus coeruleus, the brain's major noradrenergic nucleus (Aghajanian, 
1978; Crawley, 1979; Nathanson and Redmond, 1981; Laverty and 
Roth, 1981). Since lesions of noradrenergic neurons do not reduce 
clonidine's ability to decrease some behavioral signs of opioid 
withdrawal, mechanisms other than this presynaptic one have also 
been postulated (Britton, 1984). Recent studies suggest that 
clonidine also has anti-withdrawal effects on the amygdala 
(Freedman and Aghajanian, in press), spinal cord (Franz, 1982), and 
the forebrain (Matsui and Yamamoto, 1984). 
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Naltrexone precipitates withdrawal by binding to opioid 
receptors. This produces a rapid reversal in the morphine induced 
increase in the number of alpha-2 and beta receptors (Hamburg and 
Tallman, 1981) as well as reversing the opioid agonist induced 
deficiency in endogenous opioid function (Kosterlitz and Hughes, 
1975). These changes should produce a briefer, less severe 
withdrawal syndrome. 
Naltrexone also appears to equalize the time course of heroin and 
methadone withdrawal (Charney, 1982; Charney, 1986; Kleber, in 
press). The effects of naltrexone on methadone pharmacokinetics 
may be related to the reduction in the duration and symptoms of 
methadone withdrawal. Naloxone is thought to increase serum 
methadone levels in addicted patients by displacing methadone from 
opioid receptor sites (Resnick, 1979). Investigators have postulated 
that the clonidine-naltrexone regimen equalizes the length of the 
heroin and methadone withdrawal syndromes by this same 
mechanism. By displacing opioids from binding sites, naltrexone 
would eliminate the effect of opioid half-life on the time course of 
central noradrenergic normalization and of the withdrawal syndrome 
(Kleber, in press). 
In previous studies, administration of clonidine and naltrexone in 
combination to opioid dependent patients dramatically shortened the 
withdrawal syndrome without significantly increasing patient 
discomfort (Charney, 1982; Charney, 1986; Kleber, in press). The 
present study demonstrates that naltrexone, administered even 
earlier in detoxification, continued to shorten the withdrawal 
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syndrome without dramatically altering withdrawal 
symptomatology. 
An interesting effect of the addition of larger doses of naltrexone 
to the detoxification has been the decrease in the amount of clonidine 
required. Table 7 demonstrates the difference in mean daily 
clonidine doses for both inpatient and outpatient detoxifications 
using clonidine. Kleber and colleagues used clonidine and naltrexone 
in combination to detoxify heroin addicts. Naltrexone therapy began 
on day 2 using 1 mg doses which were increased every 4 hours by 1 
mg increments. This detoxification used significantly more clonidine 
than both the 4 and 5 day studies ( 4 day, p < .001; 5 day, p < .01). 
This difference might be explained by the difference in naltrexone 
dosage regimens. Patients in Kleber's study were given multiple 
small doses of naltrexone on days 2 and 3. This study administered 
the same total daily amount of naltrexone in a single morning dose. 
Small numerous doses like those used in Kleber's study might 
precipitate withdrawal repeatedly throughout days 2 and 3, 
increasing patient's withdrawal symptomatology and necessitating 
more total clonidine. A single large dose of naltrexone, although it 
initially precipitates withdrawal, is enough to remain on more opioid 
receptors for a longer period of time. Withdrawal is not precipitated 
repeatedly throughout the day, patients withdrawal symptomatology 
is not increased, and patients do not require additional clonidine. 
Lower clonidine doses, especially in the outpatient setting, is an 
additional advantage of this present study. 
Charney's studies detoxified patients from methadone 
maintenance (Charney, 1981; Charney, 1982). Both the patients 
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given clonidine therapy alone (Charney, 1981) and the patients given 
combination clonidine and naltrexone (with the naltrexone given in 
multiple, small doses), required significantly more clonidine than the 
4 and 5 day regimens described here (p < .001). This probably 
reflects the difference in the amount of clonidine required to 
detoxify patients from long-acting opioids such as methadone versus 
the clonidine required to detoxify patients from short-acting opioids 
such as heroin. When identical naltrexone dosage regimens are used 
and the amount of clonidine required per day to detoxify patients 
from methadone (Charney, 1982) is compared to the amount of 
clonidine per day required to detoxify heroin addicts (Kleber, in 
press), a significantly greater amount of clonidine is required to 
detoxify methadone patients( p<.001). 
4. CLINICAL IMPLICATIONS 
Although not definitive treatment for opioid dependence, 
withdrawal is the first step towards opioid abstinence. Methadone 
taper, clonidine therapy alone, and clonidine and naltrexone in 
combination are all effective therapeutic strategies developed 
towards this goal. Although equivalent to outpatient methadone 
taper, the efficacy of clonidine alone has been less favorable in 
outpatient than inpatient studies (Kleber et al., 1985). Combination 
clonidine and naltrexone therapy has been shown effective in both 
the inpatient and outpatient settings (Charney, 1982, Kleber et al., in 
press). However, these previous studies used small, multiple dose 
per day naltrexone regimens which could be conducted only by 
programs which had access to liquid naltrexone, a form not 
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commercially available. This study has further improved the 
availability of the clonidine-naltrexone combination by using a single 
dose per day naltrexone regimen with naltrexone doses available to 
any opioid treatment facility. Day 1 naltrexone doses are 12.5 mg, 
one quarter of the scored 50 mg naltrexone tablet (Trexan). As the 
study was conducted, some additional advantages became evident: 
the withdrawal syndrome produced by this detoxification was 
significantly shortened without significantly increasing patient 
discomfort at any point; no more clonidine was required by the 
patients in the 4 day study than what was needed by those in the 5 
day study or previous clonidine-naltrexone studies (Charney et al., 
1982; Kleber, in press); patients spent less time in clinic but 
continued to receive adequate monitoring of hypotension and 
sedation, both potentially dangerous side effects of clonidine; the 
clonidine naltrexone outpatient detoxification was effectively 
integrated with an outpatient naltrexone maintenance clinic so that 
maintenance doses of naltrexone as well as outpatient counseling 
could be continued without interruption. 
This study demonstrated that combination clonidine-naltrexone 
therapy using commercially available doses of naltrexone is an 
effective therapeutic avenue in outpatient heroin detoxification. The 
time course and patient comfort of this regimen make it a useful, 
attractive, and efficacious outpatient method for treating the acute 
opioid withdrawal syndrome. This technique can now be more 
widely used in the treatment of opioid dependence. In 
detoxifications which are not conducted for research purposes, a NCT 
would not be needed to substantiate opioid dependence. Neither 
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clonidine nor naltrexone possess any agonistic activity at opioid 
receptors and no addictive potential, qualities of methadone that 
previously attracted "pseudoaddicts" to enlist in methadone 
maintenance. Instead, 0.2 mg clonidine three times a day could be 
administered on day 1, and modifications could be made based on a 
patient's blood pressure and abstinence rating scale measurements. 
Examination of this revised clonidine dosage schedule as well as 
treatment of methadone maintained patients with an outpatient 





Characteristics of Patients 
Characteristic 5 Dav Detox 4 Dav Detox 






Years of Opioid 
Use 










NCT Score 15.5(+/- 3.3)* 15.9(+/-2.3)* # 
*Mean NCT of all those beginning study. Mean NCT of those who 
completed 5 day detoxification was unchanged; however, mean NCT 
for those who completed 4 day detoxification was 17.0 (+/-3.3). 
#N = 8, one patient in this group had a negative NCT 
Note: NCT = naloxone challenge test score from Wang (1982) with 
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Rating Scale of Withdrawal Symptoms after .8mg IM 
Naloxone* 
Score for presence or absence of symptomotologv: 
10 min. 20 min. 30 min. 




Profuse sweating 3 
Restlessness 3 
Lacrimation and 

















0 1 0 
0 1 0 
0 1 0 
0 1 0 
0 1 0 
0 1 0 
0 1 0 




DAY 1 CLONIDINE DOSES 
Predicted NCT Score Oral Clonidine HCL (mg) 
(10 minutes) 8-10 am 2 pm 8 pm 
>18 0.3 0.1-0.2 0.2 
9-17 0.2 0.1 0.1-0.2 



























PATIENT- RATED ANALOGUE SCALES 
SCALES 
ENERGY NERVOUS IRRITABILE UNINVOLVED UNPLEASANT 
COHORT 5D 4D 5D 4D 5D 4D 5D 4D 5D 4D 
DAY 
1 2.9 2.2 2.8 3.2 2.5 3.2 2.9 1.8 2.3 2.5 
2 1.6 2.5 2.5 4.0 3.4 3.0 3.8 3.5 3.4 3.0 
3 2.3 3.7 2.3 3.5 2.8 3.0 2.9 2.7 3.8 2.3 
4 4.0 3.7 2.0 2.5 2.0 3.2 1.8 2.5 1.6 1.6 
5 3.9 _ 2.1 _ 2.1 _ 2.1 - 2.4 
Note: 5D = 5 day detoxification 




COMPARISON OF DAILY CLONIDINE DOSES (MEAN +/-SD) 
A 
Study 4 Day 
B 
5 Day 
C D E 
Kleber, Charney, Charney, 
in press 1982 1981 
Day 
1 0.5 +/-0.2 0.5 +/-0.1 
2 0.5 +/-0.2 0.6 +/-0.1 
3 0.3 +/-0.1 0.4 +/-0.1 
4 0.3 +/-0.8 0.1 +/-0.1 
5 _ 0.3 +/-0.5 
6 
0.5 +/-0.2 1.1 +/-0.2 1.0 +/-0.2 
1.1 +/-0.5 2.9 +/-0.6 1.0 +/-0.2 
0.6 +/-0.3 2.3 +/-0.6 1.0 +/-0.2 
0.3 +/-0.3 0.9 +/-0.2 1.1 +/-0.3 
0.2 +/-0.2 0.5 +/-0.3 1.1 +/-0.3 
0.1 +/-0.1 0.2 +/-0.1 1.1 +/-0.3 
Note: 
4 Day = 4 days of combination clonidine and naltrexone therapy 
with naltrexone given in a single morning dose. 
5 Day = 1 day of clonidine therapy (after NCT) followed by 4 days of 
combination clonidine and naltrexone therapy with naltrexone given 
in a single morning dose. 
Kleber, in press = 1 day of clonidine therapy (after NCT) followed 
by 4 days of combination clonidine and naltrexone therapy with 
naltrexone given in multiple small doses throughout the day. 
Charney, 1982 = same as Kleber, in press, but inpatient study 
detoxing methadone patients. 
Charney, 1981 = inpatient study using clonidine alone to detoxify 
methadone patients. 
Analysis by Z test showed significant differences between A and B 
(days 2 - 4, p < .01), A and C (days 2 - 4, p < .001), A and D (days 1 - 
4, p < .001), A and E (days 1 - 4, p < .001), B and C (days 2 and 5, p < 
.001; days 3 and 4, p < .01), B and D (days 1 - 5, p < .001), and B and E 





























Figure 1 : Abstinence Rating Scale (Mean) per Day 
Mean number of signs and symptoms per patient per day, as rated 
on the 17 item observer-rated abstinence rating scale. The two 
detoxification groups were analyzed by 2-way ANOVA for repeated 
measure for the first 4 days. Time effect: F(3,63)=15.1, pc.0001; 
Treatment effect: F(l,63)= .3, p>.25; Interaction: F(3,63)=1.9, pc.25). 
1-way ANOVA analysis of each detoxification showed significant 
changes in mean ARS per day over the 4 or 5 days (5 day F(5,47)=6.6 























Figure 2: Mean Withdrawal Line per Day 
Mean withdrawal line measurement for each day. The "withdrawal 
line" is a horizontal 100 millimeter line that functions as an analogue 
scale. The left end is labeled "0- no withdrawal" and the right end is 
labeled "100- severe withdrawal." Curves represent mean scores for 
patients in the 5 or 4 day detoxification. The two plots are 
significantly different as analyzed by 2-way ANOVA for repeated 
measures for the first 4 days. Treatment: F(l,63)=6.3, pc.025; Time 


















PERCENTAGE INCREASE WITHDRAWAL LINE (MEAN) 
Day 

Figure 2B: Percentage Increase Opiate Withdrawal Line 
(mean) ner Dav Percentage increase from day 1 opiate 
withdrawal line for each day. The two detoxifications are not 
significantly different by 2-way ANOVA for repeated measure for 
the first 4 days (treatment: F(l,63) = .629, p > .25). There was a 
significant time effect and interaction (time effect: F(3,63) = 6.4, p 
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Figure 3: Mean Opiate Withdrawal Scale per Day 
Mean opiate withdrawal scale score for each day. The opiate 
withdrawal scale is a symptom checklist that functions as a self- 
rated analogue scale. It contains 38 statements pertaining to opiate 
withdrawal (e.g., "My bones and joints have been aching") which 
patients rate on a 1 (not at all) to 4 (very much so) point scale. The 
highest possible score is 152 points. The two detoxifications are 
significantly different by 2-way ANOVA for repeated measure for 
the first 4 days(treatment: F(l,63)=16.5, pc.005; time effect: 
F(3,63)=3.6, pc.025); however, there was not a significant interaction 
(F(3,63), p>.25). Only the 5 day detoxification showed a significant 
change per day as analyzed by 1-way ANOVA for repeated measures 























Figure 3B: Percentage Change Opiate Withdrawal Scale (mean) per 
Day Percentage change from day 1 opiate withdrawal scale for each 
day. The two detoxifications are not significantly different by 2-way 
ANOVA for repeated measure for the first 4 days(treatment: F(l,63) 
= .105, p > .25). There was a significant time effect and interaction 





















Figure 4 : Mean Craving Line per Dav 
Mean craving line measured each morning (prior to the 
administration of any medications) for each day. The craving line is 
a 100 millimeter horizontal line with its left end labeled "0 - no 
craving" and its right end labeled "100 - severe craving." Ratings 
significantly decreased over time for both groups by 2-way ANOVA 
for repeated measures for the first 4 days(F(3,63)=4.8, p<.01). The 






























Figure 5: Mean Systolic Blood Pressure (Standing) per Day 
Standing systolic blood pressure(BP) for each day. Day "0" represents 
"initial" systolic BP, which is the mean for all subjects of two 
measures; one taken the morning of the first day of the detoxification 
prior to the administration of any medications, and the other taken 
at least three days prior to each patients entry into the study. The 
measurements corresponding to ".5 day" represent each patients 
systolic BP immediately after the NCT prior to the administration of 
any clonidine. Day 1 measurements represent the mean of all 
systolic BP measurements taken at least one hour after the NCT and 
initial clonidine dose. Overall changes in systolic BP were significant 
as analyzed by 1-way ANOVA for repeated measures (5 day 
treatment F(5,35)=2.6, p<.05; 4 day treatment F(5,35)=6.0, pc.005). 
By 2-way ANOVA for repeated measures there was not a significant 
difference between treatments for the first 4 days (treatment: 























Figure 6: Mean Diastolic Blood Pressure (Standing) 
Standing diastolic blood pressure (BP) for each day. Graph 
clarifications as in figure 5. The two groups were significantly 
different (treatment: F(l,95)=5.8, pc.025) and had a significant 
change over time (F(5,95)= 8.2, pc.0001) as analyzed by 2-way 
ANOVA for repeated measures for the first 4 days; however, there 


























Figure 7 : Mean Heart Rate (Standing) per Dav 
Mean standing heart rate (HR) for each day. Graph clarifications as 
in figure 5. For each detoxification group, overall changes in standing 
HR were not significant as analyzed by 1-way ANOVA for repeated 
measures. Also, the two groups were not significantly different as an 























Figure 8: Mean Heart Rate (Supine) per Day 
Mean supine heart rate (HR) for each day. Graph clarifications as in 
figure 5. For patients in the 5 day detoxification, overall changes in 
supine HR were significant as analyzed by 1-way ANOVA for 
repeated measures (F(6,55)=2.7, pc.05). There were no significant 
changes in supine heart rate for patients in the 4 day detoxification 
by this analysis. The two groups differed significantly (F(l,95)=3.9, 
pc.05) and had a significant change over time (F(5,95)=6.0, pc.005) as 
analyzed by 2-way ANOVA for repeated measures. There was not a 
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